Sign In
Buy OGEN
$0.610
+0 (+0%)
At Close: Jun 03, 2026
Oragenics Q3 2025 Shareholder Update
08:30am, Wednesday, 12'th Nov 2025
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
08:00am, Tuesday, 21'st Oct 2025
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
08:30am, Tuesday, 07'th Oct 2025
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced a strategi
Oragenics Q2 2025 Shareholder Update
08:45am, Monday, 11'th Aug 2025
Advancing Brain-First Recovery Platform Toward Clinical Milestones Pioneering Intranasal Therapeutics for Concussion
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
08:39am, Wednesday, 16'th Jul 2025
SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has
Oragenics Completes Approximately $16.5 Million Offering
04:15pm, Wednesday, 02'nd Jul 2025
Proceeds to drive development of ONP-002, the Company's lead intranasal drug candidate for mild traumatic brain injury Proceeds to drive development of ONP-002, the Company's lead intranasal drug cand
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
08:31am, Tuesday, 01'st Jul 2025
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders,
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
08:30am, Tuesday, 13'th May 2025
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today anno
Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
04:30pm, Monday, 07'th Apr 2025
SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today an
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
08:30am, Thursday, 27'th Mar 2025
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundatio
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
05:33pm, Tuesday, 18'th Mar 2025
SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, to
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
09:30am, Thursday, 06'th Mar 2025
SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, to
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, tod
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
08:30am, Tuesday, 11'th Feb 2025
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat Platform Collaboration Aims to Develop First Intranasa
